Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Sponsor: Vicus Therapeutics
Listed as NCT01265576, this PHASE2 trial focuses on HCC and remains ongoing. Sponsored by Vicus Therapeutics, it has been updated 7 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Feb 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Dec 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vicus Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .